Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Rhea-AI Summary
Rigel (Nasdaq: RIGL) announced the first patient has been enrolled in the dose expansion phase of its open-label Phase 1b study of R289 in transfusion dependent relapsed/refractory lower-risk myelodysplastic syndrome (MDS) on Oct 8, 2025. The dose expansion will randomize up to 40 patients to 500 mg once daily or 500 mg twice daily to determine the recommended Phase 2 dose (RP2D).
Enrollment in the dose escalation phase completed in July 2025. The company expects to share updated study data later in 2025. R289 has FDA Orphan Drug and Fast Track designations and remains investigational and not FDA approved.
Positive
- First patient enrolled in dose expansion phase on Oct 8, 2025
- Dose escalation phase completed in July 2025
- Up to 40 patients to be randomized to define RP2D
- Orphan Drug and Fast Track designations from FDA
Negative
- R289 is investigational and not FDA approved
- Dose expansion limited to up to 40 patients, a small Phase 1b cohort
News Market Reaction 10 Alerts
On the day this news was published, RIGL declined 2.51%, reflecting a moderate negative market reaction. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $506M at that time.
Data tracked by StockTitan Argus on the day of publication.
Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS
"Today marks an important step in the evaluation of R289 for the treatment of patients with transfusion dependent lower-risk MDS, a disease with a persistent unmet need despite the availability of approved agents. In the dose expansion phase of this study, patients with transfusion dependent R/R lower-risk MDS will be randomized to receive a 500 mg R289 dose either once or twice daily," said Lisa Rojkjaer, M.D., Rigel's chief medical officer. "The outcome of this phase of the study will be the selection of the recommended Phase 2 dose of R289 for future clinical studies. We remain grateful to our investigators for their continued support of our program."
Rigel's open-label, Phase 1b study of R289 is evaluating the safety, tolerability, pharmacokinetics and preliminary activity in patients with R/R lower-risk MDS (NCT05308264). Enrollment in the dose escalation phase of the study was completed in July 2025, and the company expects to share updated data from the study later this year. In the dose expansion phase of the study, up to 40 patients will be randomized into dose levels of 500 mg once daily or 500 mg twice daily to determine the recommended Phase 2 dose (RP2D) for future development of R289. In addition, once the RP2D has been determined, an exploratory cohort of erythropoiesis-stimulating agent (ESA) R/R, or ineligible, lower-risk MDS patients will be evaluated at the RP2D.
R289 was previously granted Orphan Drug designation for the treatment of myelodysplastic syndromes and granted Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk MDS by the FDA.
About R289
R289 is a prodrug of R835, an IRAK1/4 dual inhibitor, which has been shown in preclinical studies to block inflammatory cytokine production in response to toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) family signaling. TLRs and IL-1Rs play a critical role in the innate immune response and dysregulation of these pathways can lead to various inflammatory conditions. Chronic stimulation of both these receptor systems is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients.2
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
- R289 is an investigational compound not approved by the FDA.
- Sallman DA et al. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Front Oncol. June 16, 2016. doi: https://doi.org/10.3389/fonc.2016.00151
Forward Looking Statements
This press release contains forward-looking statements relating to, among other things, the potential outcomes of the dose expansion phase of the ongoing Phase 1b study of R289, the potential benefits of R289 as a therapeutic for MDS and lower-risk MDS, the existence of patients with an unmet medical need for such therapy, and Rigel's ability to further develop its clinical stage product candidates, including the ability to share new trial data later this year. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the PSLRA. Forward-looking statements can be identified by words such as "plan", "potential", "may", "look to", "expects", "outcome", "will" and similar expressions in reference to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Rigel's current beliefs, expectations, and assumptions and hence they inherently involve significant risks, uncertainties and changes in circumstances that are difficult to predict and many of which are outside of Rigel's control. Therefore, you should not rely on any of these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks and uncertainties of clinical trials and drug development; risks and uncertainties associated with the commercialization and marketing of R289; risks that the FDA or other regulatory authorities may make adverse decisions regarding R289; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; risks that R289 may have unintended side effects, adverse reactions or incidents of misuses; the availability of resources to develop Rigel's product candidates; market competition; as well as other risks detailed from time to time in Rigel's reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and subsequent filings. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-first-patient-enrolled-in-the-dose-expansion-phase-of-its-phase-1b-study-of-r289-in-patients-with-lower-risk-mds-302577663.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What did Rigel (RIGL) announce on October 8, 2025 about R289?
How many patients will be enrolled in the R289 Phase 1b dose expansion for RIGL?
What dosing is being tested in the RIGL R289 dose expansion phase?
When did Rigel complete dose escalation for the R289 study (RIGL)?
Will Rigel (RIGL) share updated R289 clinical data in 2025?
Does R289 have any FDA designations for MDS under RIGL?
Is R289 approved by the FDA for MDS (RIGL)?
